Continued Investment in New Product Development and R&D
First written in FY2018-Q3. 13 of 24 entries say "Restated". Latest entry: FY2026-H1.
91 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the current interim consolidated accounting period was ¥2,141 million. There were no significant changes in the status of the Group’s research and development activities during the current interim consolidated accounting period.」
The Group disclosed research and development expenses of ¥2,141 million, while stating that there were no significant changes in the status of its research and development activities. - FY2025AdvancedAnnual report
「The total research and development expenses incurred by the Group during the current consolidated fiscal year were ¥3,423 million.」
Research and development expenses increased from ¥2,230 million in the previous fiscal year to ¥3,423 million. The Group has continued in-house development, industry-government-academia collaboration and advanced development, as well as the product commercialization process in collaboration with the intellectual property and quality divisions. - FY2024AdvancedAnnual report
「The total research and development expenses incurred by the Group during the current consolidated fiscal year were ¥2,230 million.」
Research and development expenses increased from ¥1,784 million in the previous fiscal year to ¥2,230 million. The Group has continued in-house development, industry-government-academia collaboration and advanced development, as well as the product commercialization process involving collaboration with the intellectual property and quality divisions. - FY2024-Q2RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the six-month cumulative period of the current fiscal year was ¥1,005 million. There were no significant changes in the status of the Group’s research and development activities during the six-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥1,005 million, while stating that there were no significant changes in the status of its research and development activities. - FY2024-Q1RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the three-month cumulative period of the current fiscal year was ¥506 million. There were no significant changes in the status of the Group’s research and development activities during the three-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥506 million, while stating that there were no significant changes in the status of its research and development activities. - FY2023AdvancedAnnual report
「The total research and development expenses incurred by the Group during the current consolidated fiscal year were ¥1,784 million.」
Research and development expenses increased from ¥1,436 million in the previous fiscal year to ¥1,784 million. In addition to in-house development, the Group advanced industry-government-academia collaboration, collaboration with the intellectual property and quality divisions, and advanced development. - FY2023-Q3RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the nine-month cumulative period of the current fiscal year was ¥1,219 million. There were no significant changes in the status of the Group’s research and development activities during the nine-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥1,219 million and stated that there were no significant changes in the status of its research and development activities. - FY2023-Q2RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the six-month cumulative period of the current fiscal year was ¥765 million. There were no significant changes in the status of the Group’s research and development activities during the six-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥765 million and stated that there were no significant changes in the status of its research and development activities. - FY2023-Q1RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the three-month cumulative period of the current fiscal year was ¥358 million. There were no significant changes in the status of the Group’s research and development activities during the three-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥358 million and stated that there were no significant changes in the status of its research and development activities. - FY2022AdvancedAnnual report
「The Group also views the Japanese archipelago as a treasure island and incorporates Japan’s outstanding traditional culture and technologies into the development of its brands and products. In technology, from the perspective of “integrating in-house development with industry-government-academia technologies,” the Group conducts in-house development with a large number of developers and researchers, while establishing a specialized incubation division and collaborating with universities, companies, government agencies and research institutions in Japan and overseas to bring together knowledge, technologies and experience from across society. It has also established an Institute of Human Engineering and incorporates technologies developed by that institute and other organizations into the development of the Group’s brands and products.」
The Group expanded its research and development framework beyond in-house development to include industry-government-academia collaboration, a specialized incubation division and use of the Institute of Human Engineering. Annual research and development expenses were ¥1,436 million. - FY2022-Q3RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the nine-month cumulative period of the current fiscal year was ¥978 million. There were no significant changes in the status of the Group’s research and development activities during the nine-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥978 million, while stating that there were no significant changes in the status of its research and development activities. - FY2022-Q2RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the six-month cumulative period of the current fiscal year was ¥620 million. There were no significant changes in the status of the Group’s research and development activities during the six-month cumulative period of the current fiscal year.」
The company disclosed research and development expenses of ¥620 million and states that there were no material changes in the status of its research and development activities. - FY2022-Q1RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the three-month cumulative period of the current fiscal year was ¥282 million. There were no significant changes in the status of the Group’s research and development activities during the three-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥282 million and stated that there were no significant changes in the status of its research and development activities. - FY2021-Q3AdvancedAnnual report
「In April 2021, as applied research for frail older people with an average age of around 90 who had been certified as requiring nursing care, the Group announced that intervention using a skeletal muscle electrical stimulation device equipped with its proprietary EMS technology was effective in maintaining and improving muscle mass and balance function. The findings were published in the international journal “Brain Sciences.”」
The Group published the results of applied research involving frail older people using its proprietary EMS technology, and the findings were published in an international journal. Research and development expenses were ¥766 million. - FY2021-Q2RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the six-month cumulative period of the current fiscal year was ¥490 million. There were no significant changes in the status of the Group’s research and development activities during the six-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥490 million and stated that there were no significant changes in the status of its research and development activities. - FY2021-Q1RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the three-month cumulative period of the current fiscal year was ¥258 million. There were no significant changes in the status of the Group’s research and development activities during the three-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥258 million and stated that there were no significant changes in the status of its research and development activities. - FY2020AdvancedAnnual report
「The total research and development expenses incurred by the Group during the current consolidated fiscal year were ¥1,462 million.」
The Group disclosed research and development expenses of ¥1,462 million and advanced the development of products and brands including NEWPEACE, ON&DO, hygiene-related products and new SIXPAD products. Research and development expenses declined from ¥1,611 million in the previous fiscal year. - FY2020-Q3AdvancedAnnual report
「In May 2020, the Group launched a new brand in the health and hygiene category and began selling disinfectant gel, medicated soap and sanitizing alcohol.」
While stating that there were no significant changes in the status of its research and development activities, the Group launched “Dokirei,” “With Mask” and “PIKO Wash!” in the health and hygiene field and began selling disinfectant gel, masks, medicated soap and hand gel. Research and development expenses were ¥1,125 million. - FY2020-Q2AdvancedAnnual report
「At beauty salons, the “ReFa BEAUTECH DRYER” and “ReFa BEAUTECH STRAIGHT IRON,” launched in October 2019, were initially sold at select salons and received highly favorable reviews. From January 2020, sales were expanded to all stores.」
While stating that there were no significant changes in the research and development activities themselves, the Group expanded the sales outlets for co-developed products from select salons to all stores and launched new products including NEWPEACE. Research and development expenses were ¥732 million. - FY2020-Q1RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the three-month cumulative period of the current fiscal year was ¥347 million. There were no significant changes in the status of the Group’s research and development activities during the three-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥347 million and stated that there were no significant changes in the status of its research and development activities. New product launches have continued, but no substantive changes from the existing policy were described. - FY2019-Q2RestatedAnnual report
「The amount spent on research and development activities by the Group as a whole during the six-month cumulative period of the current fiscal year was ¥692 million. There were no significant changes in the status of the Group’s research and development activities during the six-month cumulative period of the current fiscal year.」
The Group disclosed research and development expenses of ¥692 million, while stating that there were no significant changes in the status of its research and development activities. - FY2019-Q1AdvancedAnnual report
「The amount spent on research and development activities by the Group as a whole during the three-month cumulative period of the current fiscal year was ¥292 million.」
The Group disclosed quarterly research and development expenses of ¥292 million and launched new products under ReFa, MDNA SKIN and SIXPAD. SIXPAD products launched included Water Weight, Foot Fit and Bottom Belt. - FY2018AdvancedAnnual report
「In the BEAUTY and WELLNESS fields, we will incorporate advanced technologies such as AI and IoT into the development of our products. In particular, to further advance and develop brand creation using AI, we established the AI research institution “MTG AI Research Institute,” appointing Sugiyama Masashi (杉山 将), Director of the RIKEN Center for Advanced Intelligence Project and Professor in the Department of Complexity Science and Engineering, Graduate School of Frontier Sciences, The University of Tokyo, as a technical adviser. The institute will develop brands and products for the Group.」
The Group established the AI research institution MTG AI Research Institute and appointed a technical adviser. Research and development expenses were ¥1,977 million in the current consolidated fiscal year. - FY2018-Q3First statedAnnual report
「The amount spent on research and development activities by the Group as a whole during the nine-month cumulative period of the current fiscal year was ¥1,301 million.」
The Group disclosed research and development expenses and launched a succession of new products across its brands.